How Activities of Daily Living (ADLs) Affect Health, Independence, and Caregiving
What are Activities of Daily Living (ADLs), and why are they important? Uncover their impact on health, identity, and the strategies that support them.
Cancer screening is undergoing a transformation with GRAIL’s Galleri test. Designed for adults 50 and older, it fills critical gaps in traditional screenings and offers hope for detecting rare and aggressive cancers before symptoms appear.
Cancer screening has long been the domain of highly targeted tests, each meticulously designed to identify a specific type of cancer under stringent conditions. Let's explore the Galleri test, a marvel of modern science that rewrites that approach, aiming instead to detect over 50 types of cancer from a single blood sample. Its promise? To catch cancer when it is still curable, through surgery, when interventions can save lives and reshape prognoses.
The origins of GRAIL's Galleri test read like the opening lines of an extraordinary tale, with a surprise discovery in a very different branch of medicine. In 2015, while scientists at Illumina were refining non-invasive prenatal testing (NIPT)—a method designed to assess the health of unborn children through the mother’s blood—something unexpected surfaced. They found unusual genomic abnormalities in a subset of mothers. Initially, these anomalies seemed irrelevant to the primary goal of fetal health assessment. But as patterns emerged, the researchers realized these weren’t random glitches. Instead, they were detecting cancer signals—faint, fragmented clues from cell-free DNA (cfDNA) circulating in the mothers' blood.
This accidental discovery planted the seed for what would become a revolutionary discovery. The concept of a blood test capable of identifying cancer at its earliest stages, across multiple types, moved from improbable to plausible. GRAIL was spun off as a separate entity in 2016 to pursue this vision, its mission encapsulated in its name. If the test succeeded, it could be nothing less than the “Holy Grail” of cancer detection—a single diagnostic tool that might shift the balance in humanity’s battle against this disease.
Realizing such an ambitious goal was not simple, and required an experienced team across a broad range of expertise. It required a confluence of disciplines, drawing together the brightest minds in genomics, oncology, data science, and bioinformatics. GRAIL launched a series of rigorous studies to refine and validate the test, harnessing the power of large-scale clinical trials and cutting-edge machine learning algorithms.
The Circulating Cell-free Genome Atlas (CCGA) Study, announced in December 2016, served as the test’s cornerstone. Researchers sought to answer two critical questions: Could methylation patterns in cfDNA accurately distinguish cancer from non-cancer? And could those patterns identify the cancer’s location within the body? This foundational research involved sequencing the genomes of thousands of participants, both with and without cancer, to build a library of methylation profiles—unique markers that indicate changes in DNA activity linked to cancer.
Subsequent trials, like the STRIVE Study (2018), expanded the scope. STRIVE enrolled 100,000 women, delving deeper into the test’s ability to predict invasive cancers and ensuring its utility extended beyond theoretical potential. The SUMMIT Study, meanwhile, shifted focus to men and women without elevated cancer risk, aiming to evaluate how well the test could screen a general population for early signs of disease.
By 2020, GRAIL was ready to take the test out of purely observational studies and into clinical settings. The PATHFINDER Study represented this next phase, evaluating the practical implementation of the Galleri test among healthcare providers.
And then there was the NHS-Galleri Trial, a large collaboration with England’s National Health Service. Recruiting 140,000 participants aged 50 to 77, this trial marks one of the most ambitious efforts yet to determine the test’s effectiveness in a real-world population screening context.
To understand the Galleri test is to appreciate the convergence of genomics and artificial intelligence. The process is as elegant as it is revolutionary:
The Galleri test doesn't simply promise detection, it also promises nuanced insights.
The test has been rigorously scrutinized through pivotal studies like the CCGA (Circulating Cell-free Genome Atlas) and PATHFINDER. These efforts underscore its potential while laying bare its challenges.
The Galleri test is not a universal cancer screening tool. Its design is purposefully tailored to address specific gaps in current diagnostic practices, making it a powerful but selective option for early detection. Let’s unpack the nuances of who stands to benefit most from this innovative blood test and the context in which it is best applied.
Cancer risk increases with age, a fact that underscores the test’s primary target demographic—adults aged 50 or older. This age group experiences a rise in cancer incidence due to the cumulative effect of cellular changes, genetic mutations, and environmental exposures. For these individuals, the Galleri test offers an additional layer of vigilance, potentially catching cancers that may not yet present symptoms or fall outside the scope of routine screenings.
Within this group, there are further distinctions:
While traditional screenings like mammograms, colonoscopies, and Pap smears are effective for specific cancers, they leave substantial gaps. Many of the deadliest cancers—such as pancreatic, ovarian, and esophageal—lack established screening methods for asymptomatic individuals. This is where the Galleri test truly shines:
Despite its wide scope, the Galleri test is not a substitute for routine cancer screenings. Mammograms, colonoscopies, and other established methods have decades of evidence supporting their effectiveness for detecting certain cancers early. For example, colonoscopies not only detect colorectal cancer but can also prevent it by removing precancerous polyps.
The Galleri test supplements these methods by casting a wider net, particularly for cancers that routine screenings don’t target. Its role is additive—enhancing, not replacing, the existing arsenal of diagnostic tools. This complementary approach ensures that patients receive a comprehensive evaluation, balancing specificity and breadth.
With great promise come necessary caveats:
The promise of the Galleri test extends far beyond individual cases. Its widespread adoption could transform how healthcare systems approach cancer screening. Instead of focusing on specific cancers one at a time—breast, cervical, colorectal, for example—this test offers a panoramic view.
The ongoing NHS-Galleri trial is a litmus test for this broader vision. If successful, it could pave the way for national screening programs, where multi-cancer early detection becomes a standard offering. It also opens the door to rethinking healthcare costs, as early detection often translates to less invasive and less expensive treatments.
GRAIL continues to innovate. Its researchers are refining the test to improve sensitivity for early-stage cancers and exploring new ways to apply methylation data. They’ve also committed to funding independent research proposals, creating a global dialogue about the future of cancer diagnostics.